The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
Open accessAbstract
In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse events were recorded. At the time of a planned interim analysis, the data monitoring committee recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53). Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045). The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher tumor control rate at month 6, although it was statistically not significant, and was associated with a longer PFS than octreotide LAR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290 · cited 2×
“5 to ,2 6 (11) 14 (25) 2 to ,5 18 (34) 13 (23) 5 to ,10 11 (21) 18 (32) $10 7 (13) 7 (12) Missing 11 (21) 5 (9) Previous medications, n (%) chemotherapy 10 (19) 12 (21) immunotherapy 12 (23) 14 (25) Targeted therapy 7 (13) 8 (14) Other 14 (26) 10 (18) Missing 26 (49) 24 (42) Previous SSA use, n (%)b Octreotide lar 45…”
Cited by
Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Self-citationPavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Self-citationTelotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2780 · Cited by 303
Self-citationSomatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors
Davar, J., Connolly, H. M., Caplin, M. E., Pavel, M., Zacks, J., Bhattacharyya, S., Cuthbertson, D. J., Dobson, R., Grozinsky-Glasberg, S., Steeds, R. P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.030 · Cited by 261
Self-citation
Metadata
- Authors
- Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., Poon, D., Gadbaw, B., Li, J., Pasieka, J. L., Mahamat, A., Swahn, F., Newell-Price, J., Mansoor, W., & Öberg, K.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-09
- Volume
- 9
- Pages
- 5075
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1891914108
- Cited by
- 210
- References
- 1
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. https://app.cochat.ai/papers/10.2147/dddt.s84177
- The paper
- Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., Poon, D., Gadbaw, B., Li, J., Pasieka, J. L., Mahamat, A., Swahn, F., Newell-Price, J., Mansoor, W., & Öberg, K. (2015). Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s84177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.